This learning plan is based on IRIS Registry measure IRIS45: Exudative Age-Related Macular Degeneration: Loss of Visual Acuity. The plan reviews the impact of anti-vascular endothelial growth factor (anti-VEGF) injections in patients with wet age-related macular degeneration (AMD), including genetic predictive biomarkers of anti-VEGF treatment responses.
![RRFlogo2.jpg](/image.axd?id=dcb0d04f-0117-4126-94ba-d4a8e93846a3&t=634961810668170000)
Funded in part by the Retina Research Foundation